{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:43:40Z","timestamp":1791323020145,"version":"4.3.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s13760-025-02784-1","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T23:13:07Z","timestamp":1746227587000},"page":"819-827","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cerebrospinal fluid biomarkers of efficacy in patients affected by spinal muscular atrophy type 1 treated with nusinersen"],"prefix":"10.1007","volume":"125","author":[{"given":"Maria","family":"Sframeli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Polito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Macaione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloisa","family":"Gitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u2019hammed","family":"Aguennouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"key":"2784_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S et al (1995) Identification and characterization of a spinal muscular atrophydetermining gene. Cell 80:155\u2013165. https:\/\/doi.org\/10.1016\/0092-8674(95)90460-3","journal-title":"Cell"},{"key":"2784_CR2","doi-asserted-by":"publisher","unstructured":"Kolb SJ, Coffey CS, Yankey J W, et al. NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators. (2017) Natural history of infantile-onset spinal muscular atrophy.\u00a0Annals of neurology 82(6):883\u2013891. https:\/\/doi.org\/10.1002\/ana.25101","DOI":"10.1002\/ana.25101"},{"key":"2784_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho M, Bernal S, Al\u00edas L et al (2018) Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord 28:208\u2013215. https:\/\/doi.org\/10.1016\/j.nmd.2018.01.003","journal-title":"Neuromuscul Disord"},{"issue":"15","key":"2784_CR4","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.3390\/jcm12155060","volume":"12","author":"M Babi\u0107","year":"2023","unstructured":"Babi\u0107 M, Banovi\u0107 M, Bere\u010di\u0107 I et al (2023) Molecular Biomarkers for the Diagnosis, Prognosis, and Pharmacodynamics of Spinal Muscular Atrophy. J Clin Med 12(15):5060. https:\/\/doi.org\/10.3390\/jcm12155060","journal-title":"J Clin Med"},{"key":"2784_CR5","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT et al (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723\u20131732","journal-title":"N Engl J Med"},{"issue":"7","key":"2784_CR6","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.nmd.2018.05.010","volume":"28","author":"M Pane","year":"2018","unstructured":"Pane M, Palermo C, Messina S, Italian EAP, working group. et al (2018) Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function. Neuromuscul Disord 28(7):582\u2013585. https:\/\/doi.org\/10.1016\/j.nmd.2018.05.010. (Epub 2018 Jun 1)","journal-title":"Neuromuscul Disord"},{"key":"2784_CR7","doi-asserted-by":"publisher","unstructured":"Pane M, Coratti G, Sansone VA, et al. Italian Expanded Access Program Working Group. (2019) Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data. Ann Neurol 86(3):443\u2013451. https:\/\/doi.org\/10.1002\/ana.25533.","DOI":"10.1002\/ana.25533"},{"key":"2784_CR8","doi-asserted-by":"publisher","unstructured":"Audic F, de la Banda MGG, Bernoux D, et al. (2020) Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study. Orphanet J Rare Dis. 12;15(1):148. https:\/\/doi.org\/10.1186\/s13023-020-01414-8.","DOI":"10.1186\/s13023-020-01414-8"},{"key":"2784_CR9","doi-asserted-by":"publisher","unstructured":"Bianchi L,\u00a0Sframeli M, Vantaggiato L,\u00a0et al. (2021) Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients. Int J Mol Sci 21;22(9):4329. https:\/\/doi.org\/10.3390\/ijms22094329.","DOI":"10.3390\/ijms22094329"},{"key":"2784_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1083\/jcb.201207087","volume":"199","author":"F Rigo","year":"2012","unstructured":"Rigo F, Hua Y, Krainer AR, Bennett CF (2012) Antisense-based therapy for the treatment of spinal muscular atrophy. J Cell Biol 199:21\u201325. https:\/\/doi.org\/10.1083\/jcb.201207087","journal-title":"J Cell Biol"},{"issue":"5","key":"2784_CR11","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.20473","volume":"57","author":"KJ Swoboda","year":"2005","unstructured":"Swoboda KJ, Prior TW, Scott CB et al (2005) Natural History of Denervation in SMA: Relation to Age, SMN2 Copy Number, and Function. Ann Neurol 57(5):704\u2013712. https:\/\/doi.org\/10.1002\/ana.20473","journal-title":"Ann Neurol"},{"issue":"8","key":"2784_CR12","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14737159.2017.1341313","volume":"17","author":"A Yilmaz","year":"2017","unstructured":"Yilmaz A, Blennow K, Hagberg L, Nilsson S, Price RW, Schouten J, Spudich S, Underwood J, Zetterberg H, Gissl\u00e9n M (2017) Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev Mol Diagn 17(8):761\u2013770. https:\/\/doi.org\/10.1080\/14737159.2017.1341313","journal-title":"Expert Rev Mol Diagn"},{"key":"2784_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1146\/annurev.ne.19.030196.001155","volume":"19","author":"MK Lee","year":"1996","unstructured":"Lee MK, Cleveland DW (1996) Neuronal intermediate filaments. Annu Rev Neurosci 19:187\u2013217. https:\/\/doi.org\/10.1146\/annurev.ne.19.030196.001155","journal-title":"Annu Rev Neurosci"},{"key":"2784_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jns.2005.03.015","volume":"233","author":"A Petzold","year":"2005","unstructured":"Petzold A (2005) Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 233:183\u2013198. https:\/\/doi.org\/10.1016\/j.jns.2005.03.015","journal-title":"J Neurol Sci"},{"issue":"1","key":"2784_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/jnnp-2015-311387","volume":"87","author":"P Steinacker","year":"2016","unstructured":"Steinacker P, Feneberg E, Weishaupt J, Brettschneider J, Tumani H, Andersen PM et al (2016) Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 87(1):12\u201320. https:\/\/doi.org\/10.1136\/jnnp-2015-311387","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2784_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/s1474-4422(04)00964-0","volume":"4","author":"CE Teunissen","year":"2005","unstructured":"Teunissen CE, Dijkstra C, Polman C (2005) Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 4(1):32\u201341. https:\/\/doi.org\/10.1016\/s1474-4422(04)00964-0","journal-title":"Lancet Neurol"},{"key":"2784_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/jns.12279","volume":"23","author":"S Mariotto","year":"2018","unstructured":"Mariotto S, Farinazzo A, Magliozzi R, Alberti D, Monaco S, Ferrari S (2018) Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. J Peripher Nerv Syst 23:174\u2013177. https:\/\/doi.org\/10.1111\/jns.12279","journal-title":"J Peripher Nerv Syst"},{"issue":"9","key":"2784_CR18","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00415-019-09389-8","volume":"266","author":"B Olsson","year":"2019","unstructured":"Olsson B, Alberg L, Cullen NC, Michael E, Wahlgren L, Kroksmark AK, Rostasy K, Blennow K, Zetterberg H, Tulinius M (2019) NFL is a marker of treatment response in children with SMA treated with nusinersen. J Neurol 266(9):2129\u20132136. https:\/\/doi.org\/10.1007\/s00415-019-09389-8","journal-title":"J Neurol"},{"issue":"23","key":"2784_CR19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.omtm.2021.10.011","volume":"30","author":"CRR Alves","year":"2021","unstructured":"Alves CRR, Petrillo M, Spellman R, Garner R, Zhang R, Kiefer M et al (2021) Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: A case series. Mol Ther Methods Clin Dev 30(23):524\u2013538. https:\/\/doi.org\/10.1016\/j.omtm.2021.10.011","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10","key":"2784_CR20","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1002\/acn3.51449","volume":"8","author":"E Nitz","year":"2021","unstructured":"Nitz E, Smitka M, Schallner J, Akg\u00fcn K, Ziemssen T, von der Hagen M, T\u00fcngler V (2021) Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children. Ann Clin Transl Neurol 8(10):2013\u20132024. https:\/\/doi.org\/10.1002\/acn3.51449","journal-title":"Ann Clin Transl Neurol"},{"key":"2784_CR21","doi-asserted-by":"publisher","unstructured":"Bayoumy S, Verberk IMW, Vermunt L, Willemse E, den Dulk B, van der Ploeg AT, et al. (2024) Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges. Clin Chem Lab Med. 15. https:\/\/doi.org\/10.1515\/cclm-2023-1311","DOI":"10.1515\/cclm-2023-1311"},{"issue":"2","key":"2784_CR22","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1046\/j.1471-4159.1999.0720741.x","volume":"72","author":"FP Zemlan","year":"1999","unstructured":"Zemlan FP, Rosenberg WS, Luebbe PA, Campbell TA, Dean GE, Weiner NE, Cohen JA, Rudick RA, Woo D (1999) Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J Neurochem 72(2):741\u2013750. https:\/\/doi.org\/10.1046\/j.1471-4159.1999.0720741.x","journal-title":"J Neurochem"},{"issue":"4","key":"2784_CR23","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/jamaneurol.2013.6064","volume":"71","author":"M Grossman","year":"2014","unstructured":"Grossman M, Elman L, McCluskey L, McMillan CT, Boller A, Powers J, Rascovsky K, Hu W, Shaw L, Irwin DJ, Lee VM, Trojanowski JQ (2014) Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA Neurol 71(4):442\u2013448. https:\/\/doi.org\/10.1001\/jamaneurol.2013.6064","journal-title":"JAMA Neurol"},{"issue":"11","key":"2784_CR24","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1007\/s00415-018-9043-0","volume":"265","author":"S Schreiber","year":"2018","unstructured":"Schreiber S, Spotorno N, Schreiber F, Acosta-Cabronero J, Kaufmann J, Machts J et al (2018) Significance of CSF NfL and tau in ALS. J Neurol 265(11):2633\u20132645. https:\/\/doi.org\/10.1007\/s00415-018-9043-0","journal-title":"J Neurol"},{"issue":"10","key":"2784_CR25","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1007\/s00415-018-9008-3","volume":"265","author":"A Scarafino","year":"2018","unstructured":"Scarafino A, D\u2019Errico E, Introna A, Fraddosio A, Distaso E, Tempesta I, Morea A, Mastronardi A, Leante R, Ruggieri M, Mastrapasqua M, Simone IL (2018) Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis. J Neurol 265(10):2353\u20132362. https:\/\/doi.org\/10.1007\/s00415-018-9008-3","journal-title":"J Neurol"},{"issue":"6","key":"2784_CR26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/acn3.51562","volume":"9","author":"RS Finkel","year":"2022","unstructured":"Finkel RS, Ryan MM, Pascual Pascual SI et al (2022) Scientific rationale for a higher dose of nusinersen. Annals of Clinical and Translational Neurology 9(6):819\u2013829. https:\/\/doi.org\/10.1002\/acn3.51562","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"2784_CR27","doi-asserted-by":"publisher","unstructured":"Totzeck A, Stolte B, Kizina K, Bolz S, Schlag M, Thimm A, Kleinschnitz C, Hagenacker T. (2019) Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen. Int J Mol Sci. 30;20(21):5397. https:\/\/doi.org\/10.3390\/ijms20215397.","DOI":"10.3390\/ijms20215397"},{"issue":"5","key":"2784_CR28","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1111\/jcmm.14939","volume":"24","author":"I Faravelli","year":"2020","unstructured":"Faravelli I, Meneri M, Saccomanno D, Velardo D, Abati E, Gagliardi D et al (2020) Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients. J Cell Mol Med 24(5):3034\u20133039. https:\/\/doi.org\/10.1111\/jcmm.14939","journal-title":"J Cell Mol Med"},{"issue":"12","key":"2784_CR29","doi-asserted-by":"publisher","first-page":"175628641984605","DOI":"10.1177\/1756286419846058","volume":"10","author":"CD Wurster","year":"2019","unstructured":"Wurster CD, G\u00fcnther R, Steinacker P, Dreyhaupt J, Wollinsky K, Uzelac Z et al (2019) Neurochemical Markers in CSF of Adolescent and Adult SMA Patients Undergoing Nusinersen Treatment. Ther Adv Neurol Disord 10(12):1756286419846058. https:\/\/doi.org\/10.1177\/1756286419846058","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"2784_CR30","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3233\/JND-230054","volume":"10","author":"J Glascock","year":"2023","unstructured":"Glascock J, Darras BT, Crawford TO, Sumner CJ, Kolb SJ, DiDonato C, Elsheikh B, Howell K, Farwell W, Valente M, Petrillo M, Tingey J, Jarecki J (2023) Identifying Biomarkers of Spinal Muscular Atrophy for Further Development. J Neuromuscul Dis 10(5):937\u2013954. https:\/\/doi.org\/10.3233\/JND-230054","journal-title":"J Neuromuscul Dis"},{"issue":"3","key":"2784_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","volume":"20","author":"AM Glanzman","year":"2010","unstructured":"Glanzman AM, Mazzone E, Main M, Pelliccioni M, Wood J, Swoboda KJ, Scott C, Pane M, Messina S, Bertini E, Mercuri E, Finkel RS (2010) The Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord 20(3):155\u2013161. https:\/\/doi.org\/10.1016\/j.nmd.2009.11.014","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"2784_CR32","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3233\/jad-161114","volume":"58","author":"KD Deters","year":"2017","unstructured":"Deters KD, Risacher SL, Kim S, Nho K, West JD, Blennow K, Zetterberg H, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ, Initiative ADN (2017) Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer\u2019s Disease. J Alzheimers Dis 58(4):1245\u20131254. https:\/\/doi.org\/10.3233\/jad-161114","journal-title":"J Alzheimers Dis"},{"key":"2784_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1212\/wnl.0000000000004761","volume":"90","author":"E Feneberg","year":"2018","unstructured":"Feneberg E, Oeckl P, Steinacker P, Verde F, Barro C, Van Damme P et al (2018) Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology 90:22\u201330. https:\/\/doi.org\/10.1212\/wnl.0000000000004761","journal-title":"Neurology"},{"key":"2784_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0960-8966(91)90051-s","volume":"1","author":"V Dubowitz","year":"1991","unstructured":"Dubowitz V (1991) Chaos in Classification of the Spinal Muscular Atrophies of Childhood. Neuromuscul Disord 1:77\u201380. https:\/\/doi.org\/10.1016\/0960-8966(91)90051-s","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"2784_CR35","doi-asserted-by":"publisher","first-page":"e696","DOI":"10.1212\/wnl.0000000000006050","volume":"91","author":"M Pane","year":"2018","unstructured":"Pane M, Palermo C, Messina S, Sansone VA, Bruno C, Catteruccia M et al (2018) An Observational Study of Functional Abilities in Infants, Children, and Adults with Type 1 SMA. Neurology 91(8):e696\u2013e703. https:\/\/doi.org\/10.1212\/wnl.0000000000006050","journal-title":"Neurology"},{"issue":"3","key":"2784_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14051","volume":"30","author":"G \u0160imi\u0107","year":"2024","unstructured":"\u0160imi\u0107 G, Vuki\u0107 V, Babi\u0107 M et al (2024) Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1\u20133 patients treated with nusinersen. CNS Neurosci Ther 30(3):e14051. https:\/\/doi.org\/10.1111\/cns.14051","journal-title":"CNS Neurosci Ther"},{"issue":"3","key":"2784_CR37","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.neures.2009.11.012","volume":"66","author":"N Mattsson","year":"2010","unstructured":"Mattsson N, S\u00e4vman K, Osterlundh G, Blennow K, Zetterberg H (2010) Converging molecular pathways in human neural development and degeneration. Neurosci Res 66(3):330\u2013332. https:\/\/doi.org\/10.1016\/j.neures.2009.11.012","journal-title":"Neurosci Res"},{"issue":"3","key":"2784_CR38","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.braindev.2019.12.006","volume":"42","author":"T Tozawa","year":"2020","unstructured":"Tozawa T, Kasai T, Tatebe H, Shiomi K, Nishio H, Tokuda T, Chiyonobu T (2020) Intrathecal nusinersen treatment after ventriculo-peritoneal shunt placement: A case report focusing on the neurofilament light chain in cerebrospinal fluid. Brain Dev 42(3):311\u2013314. https:\/\/doi.org\/10.1016\/j.braindev.2019.12.006","journal-title":"Brain Dev"},{"issue":"1","key":"2784_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.pediatrneurol.2013.02.015","volume":"49","author":"P Shahim","year":"2013","unstructured":"Shahim P, Darin N, Andreasson U, Blennow K, Jennions E, Lundgren J, M\u00e5nsson JE, Naess K, T\u00f6rnhage CJ, Zetterberg H, Mattsson N (2013) Cerebrospinal fluid brain injury biomarkers in children: a multicenter study. Pediatr Neurol 49(1):31-39.e2. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2013.02.015","journal-title":"Pediatr Neurol"},{"issue":"17","key":"2784_CR40","doi-asserted-by":"publisher","first-page":"8419","DOI":"10.1111\/jcmm.16802","volume":"25","author":"J Johannsen","year":"2021","unstructured":"Johannsen J, Weiss D, Daubmann A, Schmitz L, Denecke J (2021) Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen. J Cell Mol Med 25(17):8419\u20138431. https:\/\/doi.org\/10.1111\/jcmm.16802","journal-title":"J Cell Mol Med"},{"issue":"4","key":"2784_CR41","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/jama.2009.1064","volume":"302","author":"N Mattsson","year":"2009","unstructured":"Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M et al (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302(4):385\u2013393. https:\/\/doi.org\/10.1001\/jama.2009.1064","journal-title":"JAMA"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-025-02784-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-025-02784-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-025-02784-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T02:14:39Z","timestamp":1748657679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-025-02784-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2784"],"URL":"https:\/\/doi.org\/10.1007\/s13760-025-02784-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5143433\/v1","asserted-by":"object"}]},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,3]]},"assertion":[{"value":"24 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of the province of Messina (protocol code 91\/16) and conducted according to the guidelines of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Committee Statement"}}]}}